according to the results of a retrospective analysis conducted by researchers at Memorial Sloan Kettering. Their analysis included 396 patients, 14.1% of which received treatment with Opdivo, while the rest received Keytruda (pembrolizumab).
the overall survival was 11.3 to 15.5 months (median 12.8 months). In patients taking cisplatin and fluorouracil, the overall survival was 9.4 to 11.9 months (median 10.7 months). The complete response rate was 13.4%, 11.1